NASDAQ:RVNC

Revance Therapeutics News Headlines

$27.24
+0.02 (+0.07 %)
(As of 04/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.81
Now: $27.24
$27.78
50-Day Range
$24.03
MA: $27.47
$29.30
52-Week Range
$15.52
Now: $27.24
$34.62
Volume265,664 shs
Average Volume439,650 shs
Market Capitalization$1.94 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.42

Headlines

Revance Therapeutics (NASDAQ RVNC) News Headlines Today

SourceHeadline
Revance Therapeutics (RVNC) Buy Rating Reaffirmed at Needham & Company LLCRevance Therapeutics' (RVNC) Buy Rating Reaffirmed at Needham & Company LLC
marketbeat.com - April 14 at 7:59 AM
Needham & Company LLC Reiterates Buy Rating for Revance Therapeutics (NASDAQ:RVNC)Needham & Company LLC Reiterates Buy Rating for Revance Therapeutics (NASDAQ:RVNC)
americanbankingnews.com - April 14 at 8:48 AM
BRIEF-Revance Says Co, Lyophilization Services Of New England Entered Commercial Supply AgreementBRIEF-Revance Says Co, Lyophilization Services Of New England Entered Commercial Supply Agreement
msn.com - April 12 at 4:28 PM
Revance to Participate in the 20th Annual Needham Virtual Healthcare ConferenceRevance to Participate in the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 6 at 7:39 PM
Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at the American Academy of Neurology Annual 2021 Virtual MeetingRevance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at the American Academy of Neurology Annual 2021 Virtual Meeting
finance.yahoo.com - April 1 at 9:58 AM
Fortune Names Revance to the Top 10 Best Workplaces in Biopharma in 2021Fortune Names Revance to the Top 10 Best Workplaces in Biopharma in 2021
finance.yahoo.com - March 22 at 7:21 PM
Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 5.4% Jump Turn into More Strength?Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 5.4% Jump Turn into More Strength?
finance.yahoo.com - March 22 at 2:20 PM
Investors Who Bought Revance Therapeutics (NASDAQ:RVNC) Shares A Year Ago Are Now Up 73%Investors Who Bought Revance Therapeutics (NASDAQ:RVNC) Shares A Year Ago Are Now Up 73%
finance.yahoo.com - March 12 at 7:03 PM
Revance to Participate in Upcoming Virtual Healthcare ConferencesRevance to Participate in Upcoming Virtual Healthcare Conferences
finance.yahoo.com - February 24 at 5:48 PM
Revance Therapeutics DaxibotulinumtoxinA For Injection Improves Muscle Tone In Mid-Stage Upper Limb SpasticityRevance Therapeutics' DaxibotulinumtoxinA For Injection Improves Muscle Tone In Mid-Stage Upper Limb Spasticity
finance.yahoo.com - February 23 at 10:12 AM
Recap: Revance Therapeutics Q4 EarningsRecap: Revance Therapeutics Q4 Earnings
finance.yahoo.com - February 22 at 11:18 PM
Revance Reports Fourth Quarter and Full Year 2020 Financial ResultsRevance Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - February 22 at 6:16 PM
Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb SpasticityRevance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity
finance.yahoo.com - February 22 at 6:16 PM
Revance Appoints Biotech and Pharmaceutical Executive, Olivia C. Ware, and Fintech and Payments Thought Leader and Entrepreneur, Carey O’Connor Kolaja, to its Board of DirectorsRevance Appoints Biotech and Pharmaceutical Executive, Olivia C. Ware, and Fintech and Payments Thought Leader and Entrepreneur, Carey O’Connor Kolaja, to its Board of Directors
finance.yahoo.com - February 22 at 8:15 AM
Heres what Wall Street expects from Revance Therapeuticss earnings reportHere's what Wall Street expects from Revance Therapeutics's earnings report
markets.businessinsider.com - February 20 at 1:31 PM
Revance Therapeuticss Earnings OutlookRevance Therapeutics's Earnings Outlook
finance.yahoo.com - February 19 at 2:24 PM
Revance to Release Fourth Quarter and Full Year 2020 Financial Results on Monday, February 22, 2021Revance to Release Fourth Quarter and Full Year 2020 Financial Results on Monday, February 22, 2021
finance.yahoo.com - February 12 at 10:16 AM
Revance to Highlight Aesthetic Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Study Results at Maui Derm for Dermatologists 2021Revance to Highlight Aesthetic Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Study Results at Maui Derm for Dermatologists 2021
finance.yahoo.com - January 25 at 9:09 AM
What Is The Ownership Structure Like For Revance Therapeutics, Inc. (NASDAQ:RVNC)?What Is The Ownership Structure Like For Revance Therapeutics, Inc. (NASDAQ:RVNC)?
finance.yahoo.com - January 11 at 3:20 PM
Revance to Participate in the 39th Annual J.P. Morgan Healthcare ConferenceRevance to Participate in the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 7 at 6:33 PM
Revance Provides Corporate Update and Anticipated Milestones for 2021Revance Provides Corporate Update and Anticipated Milestones for 2021
finance.yahoo.com - January 7 at 8:29 AM
Revance Reports Positive Efficacy and Duration Results from Phase 2 Upper Facial Lines StudyRevance Reports Positive Efficacy and Duration Results from Phase 2 Upper Facial Lines Study
finance.yahoo.com - December 17 at 9:18 AM
Is RVNC A Good Stock To Buy Now?Is RVNC A Good Stock To Buy Now?
finance.yahoo.com - December 14 at 2:30 PM
Revances (RVNC) DaxibotulinumtoxinA BLA Decision DelayedRevance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed
finance.yahoo.com - November 27 at 4:24 PM
FDA defers BLA decision on Revances frown lines treatmentFDA defers BLA decision on Revance's frown lines treatment
seekingalpha.com - November 25 at 1:49 PM
FDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site InspectionFDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspection
finance.yahoo.com - November 25 at 8:49 AM
Revance to Participate in the Piper Sandler 32nd Annual Virtual Healthcare ConferenceRevance to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
finance.yahoo.com - November 24 at 7:05 PM
Endeavor lands biotech HQ for new Nashville high-riseEndeavor lands biotech HQ for new Nashville high-rise
bizjournals.com - November 24 at 9:04 AM
Bay Area biotech company moving HQ to downtown Nashville, leasing top floor of office towerBay Area biotech company moving HQ to downtown Nashville, leasing top floor of office tower
bizjournals.com - November 23 at 6:01 PM
East Bay biotech maps route for HQ road trip to NashvilleEast Bay biotech maps route for HQ road trip to Nashville
bizjournals.com - November 23 at 1:01 PM
Revances Daxi flunks in plantar fasciitis studyRevance's Daxi flunks in plantar fasciitis study
seekingalpha.com - November 12 at 10:57 AM
Analysts Have Made A Financial Statement On Revance Therapeutics, Inc.s (NASDAQ:RVNC) Third-Quarter ReportAnalysts Have Made A Financial Statement On Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Third-Quarter Report
finance.yahoo.com - November 11 at 1:06 PM
Revance to Participate in the Stifel 2020 Virtual Healthcare ConferenceRevance to Participate in the Stifel 2020 Virtual Healthcare Conference
finance.yahoo.com - November 10 at 8:34 PM
Revance Daxi flunks in plantar fasciitis studyRevance' Daxi flunks in plantar fasciitis study
seekingalpha.com - November 10 at 10:32 AM
Recap: Revance Therapeutics Q3 EarningsRecap: Revance Therapeutics Q3 Earnings
benzinga.com - November 9 at 6:13 PM
Revance Therapeutics EPS misses by $0.30, beats on revenue; updates FY20 outlookRevance Therapeutics EPS misses by $0.30, beats on revenue; updates FY20 outlook
seekingalpha.com - November 9 at 6:13 PM
Revance Therapeutics, Inc. to Host Earnings CallRevance Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 6:13 PM
Revance Announces Results of Phase 2 Trial of DaxibotulinumtoxinA for Injection in Plantar FasciitisRevance Announces Results of Phase 2 Trial of DaxibotulinumtoxinA for Injection in Plantar Fasciitis
finance.yahoo.com - November 9 at 6:13 PM
Revance Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateRevance Reports Third Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 6:13 PM
Is a Surprise Coming for Revance (RVNC) This Earnings Season?Is a Surprise Coming for Revance (RVNC) This Earnings Season?
finance.yahoo.com - November 6 at 2:23 PM
Revance to Participate in the Credit Suisse 29th Annual Healthcare ConferenceRevance to Participate in the Credit Suisse 29th Annual Healthcare Conference
finance.yahoo.com - November 3 at 8:37 PM
Revance to Release Third Quarter 2020 Financial Results on Monday, November 9, 2020Revance to Release Third Quarter 2020 Financial Results on Monday, November 9, 2020
finance.yahoo.com - November 2 at 5:38 PM
Revance Therapeutics Inc. Regis (RTI.SG)Revance Therapeutics Inc. Regis (RTI.SG)
in.finance.yahoo.com - October 15 at 2:17 PM
Revances lead candidate successful in late-stage study in neck movement disorderRevance's lead candidate successful in late-stage study in neck movement disorder
seekingalpha.com - October 14 at 1:29 PM
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - September 23 at 8:04 PM
Stock Alert: Revance Therapeutics Gains 8%Stock Alert: Revance Therapeutics Gains 8%
nasdaq.com - September 15 at 3:08 PM
Revance to Participate in the Wells Fargo Securities Healthcare ConferenceRevance to Participate in the Wells Fargo Securities Healthcare Conference
finance.yahoo.com - September 2 at 9:43 AM
Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?
finance.yahoo.com - August 28 at 12:34 PM
RVNC.O - Revance Therapeutics Inc Profile | ReutersRVNC.O - Revance Therapeutics Inc Profile | Reuters
reuters.com - August 16 at 9:10 AM
NetworkNewsBreaks - Revance Therapeutics, Inc. (NASDAQ: RVNC) Featured in Mizuho Securities Research ReportNetworkNewsBreaks - Revance Therapeutics, Inc. (NASDAQ: RVNC) Featured in Mizuho Securities Research Report
marketwatch.com - August 11 at 3:28 PM
Revance Announces Two Peer-Reviewed Publications Reporting Safety and Efficacy Results from the SAKURA 3 Open-Label Safety Study in Dermatologic SurgeryRevance Announces Two Peer-Reviewed Publications Reporting Safety and Efficacy Results from the SAKURA 3 Open-Label Safety Study in Dermatologic Surgery
finance.yahoo.com - August 11 at 9:27 AM
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.